SEC Form 4 · accession 0001567619-18-006564
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
Nov 14, 2018
Accepted (ET)
Nov 16, 2018 · 7:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 14, 2018 | M | 9,000 | $63.10 | A | 58,135 | D | |
| Common StockF1,F2 | Nov 14, 2018 | S | 5,201 | $91.6158 | D | 52,934 | D | |
| Common StockF1,F3 | Nov 14, 2018 | S | 2,400 | $92.207 | D | 50,534 | D | |
| Common StockF1,F4 | Nov 14, 2018 | S | 799 | $93.8139 | D | 49,735 | D | |
| Common StockF1,F5 | Nov 14, 2018 | S | 600 | $94.3516 | D | 49,135 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F6 | $63.10 | Nov 14, 2018 | M | 9,000 | D | Dec 4, 2014 | Jun 3, 2024 | Common Stock | 9,000 | 30,700 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 10, 2018.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $91.01 to $92.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3The price in column 4 is the weighted average price. The price actually received ranged from $92.01 to $92.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F4The price in column 4 is the weighted average price. The price actually received ranged from $93.12 to $94.09. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F5The price in column 4 is the weighted average price. The price actually received ranged from $94.13 to $94.66. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F6Reflects the number of options outstanding after the transactions from this specific stock option grant.